2 October 2017 in PLOS Pathogens
We have shown previously that Sp100 (a component of the ND10 nuclear body) represses transcription, replication and establishment of incoming human papillomavirus (HPV) DNA in the early stages of infection. In this follow up study, we show that Sp100 does not substantially regulate viral infection in the maintenance phase, however at late stages of infection Sp100 interacts with amplifying viral genomes to repress viral processes. We find that Sp100 localizes to HPV16 replication foci generated in primary keratinocytes, to HPV31 replication foci that form in differentiated cells, and to HPV16 replication foci in CIN 1 cervical biopsies. To analyze this further, Sp100 was down regulated by siRNA treatment of differentiating HPV31 containing cells and levels of viral transcription and replication were assessed. This revealed that Sp100 represses viral transcription and replication in differentiated cells. Analysis of Sp100 binding to viral chromatin showed that Sp100 bound across the viral genome, and that binding increased at late stages of infection. Therefore, Sp100 represses the HPV life cycle at both early and late stages of infection. Host restriction factors act to limit viral infection as part of the intrinsic immune system. Upon entry into cells, human papillomaviruses (HPV) encounter anti-viral nuclear bodies, called ND10, and components of these bodies, such as Sp100, restrict early viral infection. If HPV escapes these defenses, it can establish a long-term, persistent infection. The eventual production of infectious HPV particles depends on the differentiation program of host keratinocytes. Here we show that in the transition from persistent to productive infection in differentiated keratinocytes, HPV again engages the Sp100 component of ND10 bodies. Sp100 is observed surrounding and inside replication centers in differentiated cells in culture, and in HPV-infected cervical lesions. This results in restriction of viral DNA amplification and late viral gene expression. These data collectively show that Sp100 mediates an anti-viral response at both early and late stages of viral infection.
27 April 2023 in Journal of Virology
Studies suggest that the protection against SIV/simian-human immunodeficiency virus (SHIV) acquisition afforded by the SIV/HIV V1 deletion-containing envelope immunogens, delivered by the DNA/ALVAC vaccine platform, requires multiple innate and adaptive host responses. Anti-inflammatory macrophages and tolerogenic dendritic cells (DC-10), together with CD14 + efferocytes, are consistently found to correlate with a vaccine-induced decrease in the risk of SIV/SHIV acquisition.